UY39522A - Anticuerpos de cadena pesada que se unen al receptor alfa de folato - Google Patents
Anticuerpos de cadena pesada que se unen al receptor alfa de folatoInfo
- Publication number
- UY39522A UY39522A UY0001039522A UY39522A UY39522A UY 39522 A UY39522 A UY 39522A UY 0001039522 A UY0001039522 A UY 0001039522A UY 39522 A UY39522 A UY 39522A UY 39522 A UY39522 A UY 39522A
- Authority
- UY
- Uruguay
- Prior art keywords
- heavy
- chain antibodies
- bind
- alpha receptor
- folate
- Prior art date
Links
- 229940014144 folate Drugs 0.000 title 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title 1
- 235000019152 folic acid Nutrition 0.000 title 1
- 239000011724 folic acid Substances 0.000 title 1
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 3
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 3
- 230000003432 anti-folate effect Effects 0.000 abstract 1
- 229940127074 antifolate Drugs 0.000 abstract 1
- 239000004052 folic acid antagonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen anticuerpos de cadena pesada del receptor alfa anti-folato (FOLR1) (por ejemplo, UniAbsTM), junto con métodos para elaborar tales anticuerpos, composiciones, incluidas las composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión del receptor alfa de folato (FOLR1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063115436P | 2020-11-18 | 2020-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39522A true UY39522A (es) | 2022-06-30 |
Family
ID=79024440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039522A UY39522A (es) | 2020-11-18 | 2021-11-18 | Anticuerpos de cadena pesada que se unen al receptor alfa de folato |
Country Status (17)
Country | Link |
---|---|
US (1) | US20240002498A1 (es) |
EP (1) | EP4247498A1 (es) |
JP (1) | JP2023549851A (es) |
KR (1) | KR20230110303A (es) |
CN (1) | CN116615253A (es) |
AR (1) | AR124084A1 (es) |
AU (1) | AU2021383743A1 (es) |
CA (1) | CA3199785A1 (es) |
CL (1) | CL2023001432A1 (es) |
CO (1) | CO2023006790A2 (es) |
CR (1) | CR20230259A (es) |
IL (1) | IL302670A (es) |
MX (1) | MX2023005693A (es) |
PE (1) | PE20231203A1 (es) |
TW (1) | TW202233684A (es) |
UY (1) | UY39522A (es) |
WO (1) | WO2022109010A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
MX2021015337A (es) | 2019-06-14 | 2022-01-18 | Teneobio Inc | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
PL2406284T3 (pl) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Przeciwciała anty-bcma |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US20140308285A1 (en) * | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
EP3789402B1 (en) * | 2014-11-20 | 2022-07-13 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
JP7146395B2 (ja) * | 2014-11-20 | 2022-10-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | FolR1及びCD3を標的とする二重特異性抗体 |
EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
US20190225671A1 (en) | 2016-08-24 | 2019-07-25 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
PT4050034T (pt) | 2016-09-14 | 2024-05-27 | Teneoone Inc | Anticorpos de ligação a cd3 |
SG11202007494TA (en) * | 2018-03-13 | 2020-09-29 | Phanes Therapeutics Inc | Anti-folate receptor 1 antibodies and uses thereof |
-
2021
- 2021-11-11 TW TW110142033A patent/TW202233684A/zh unknown
- 2021-11-17 US US18/253,197 patent/US20240002498A1/en active Pending
- 2021-11-17 PE PE2023001680A patent/PE20231203A1/es unknown
- 2021-11-17 IL IL302670A patent/IL302670A/en unknown
- 2021-11-17 CR CR20230259A patent/CR20230259A/es unknown
- 2021-11-17 JP JP2023528641A patent/JP2023549851A/ja active Pending
- 2021-11-17 WO PCT/US2021/059701 patent/WO2022109010A1/en active Application Filing
- 2021-11-17 KR KR1020237020120A patent/KR20230110303A/ko unknown
- 2021-11-17 MX MX2023005693A patent/MX2023005693A/es unknown
- 2021-11-17 CN CN202180077625.6A patent/CN116615253A/zh active Pending
- 2021-11-17 CA CA3199785A patent/CA3199785A1/en active Pending
- 2021-11-17 AR ARP210103178A patent/AR124084A1/es unknown
- 2021-11-17 AU AU2021383743A patent/AU2021383743A1/en active Pending
- 2021-11-17 EP EP21824720.3A patent/EP4247498A1/en active Pending
- 2021-11-18 UY UY0001039522A patent/UY39522A/es unknown
-
2023
- 2023-05-18 CL CL2023001432A patent/CL2023001432A1/es unknown
- 2023-05-25 CO CONC2023/0006790A patent/CO2023006790A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021383743A9 (en) | 2024-09-26 |
PE20231203A1 (es) | 2023-08-17 |
EP4247498A1 (en) | 2023-09-27 |
JP2023549851A (ja) | 2023-11-29 |
MX2023005693A (es) | 2023-05-29 |
IL302670A (en) | 2023-07-01 |
TW202233684A (zh) | 2022-09-01 |
CL2023001432A1 (es) | 2024-01-05 |
WO2022109010A1 (en) | 2022-05-27 |
AR124084A1 (es) | 2023-02-08 |
KR20230110303A (ko) | 2023-07-21 |
AU2021383743A1 (en) | 2023-06-08 |
US20240002498A1 (en) | 2024-01-04 |
CR20230259A (es) | 2023-07-13 |
CN116615253A (zh) | 2023-08-18 |
CO2023006790A2 (es) | 2023-06-09 |
CA3199785A1 (en) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002586A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
CO2023006790A2 (es) | Anticuerpos de cadena pesada que se unen al receptor de folato alfa | |
CL2021003196A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850) | |
EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
AR119746A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
CL2018003438A1 (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos. | |
BR112016004073A8 (pt) | Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3 | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
DOP2022000229A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
CL2022002247A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 (divisional de la solicitud 202001703) | |
UY39191A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
BR112016020871A2 (pt) | anticorpos anti-mcam e métodos associados de uso | |
UY39715A (es) | Anticuerpos anti-il-2r agonistas y métodos de uso | |
CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
MX2020004265A (es) | Conjugados de anticuerpos y farmacos de factor anti-tisular y su uso en el tratamiento del cancer. | |
CO2023000808A2 (es) | Unión de anticuerpos multiespecíficos a bcma | |
CL2023001220A1 (es) | Inhibidores de interleucina-17 | |
CO2023013500A2 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
CL2022001677A1 (es) | Anticuerpos anti-ccl2 biespecíficos | |
MX2019015120A (es) | Composicion y metodo para el tratamiento de la depresion y psicosis en humanos. | |
BR112022013553A2 (pt) | Composição farmacêutica, anticorpo, e, método para tratar uma doença |